[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335374-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335374-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comorbidity-in-patients-with-cancer-treated-at-the-christie-clinical-studies-prevalence-and-patterns-using-ace-27","Comorbidity in patients with cancer treated at The Christie - Clinical Studies - Prevalence and patterns using ACE-27","","Comorbidities affect how cancer presents and how patients are treated, influencing health, care, and outcomes. This study examines the prevalence and patterns of comorbidity across a pan-cancer cohort treated at The Christie in the UK over a 9-year period. A retrospective review of 77,149 patients (2014–2022) used ACE-27 across 12 organ systems and overall burden, applying logistic regression to relate incidence to demographic and socio-economic factors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comorbidity-in-patients-with-cancer-treated-at-the-christie-clinical-studies-prevalence-and-patterns-using-ace-27/335374/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comorbidity-in-patients-with-cancer-treated-at-the-christie-clinical-studies-prevalence-and-patterns-using-ace-27/335374.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the aim of this study on comorbidity in cancer patients?","Question",{"text":63,"@type":64},"To investigate the prevalence and patterns of comorbidity in a pan-cancer cohort treated at The Christie over a 9-year period.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were comorbidities measured and analyzed?",{"text":68,"@type":64},"A retrospective review of 77,149 patients used the Adult Comorbidity Evaluation 27 (ACE-27) to assess comorbidity burden across 12 organ systems and overall burden, with binary and multinomial logistic regressions to test relationships with demographic and socio-economic factors.",{"name":70,"@type":61,"acceptedAnswer":71},"What patient factors were associated with higher comorbidity incidence or severity?",{"text":72,"@type":64},"Comorbidity severity was higher in patients from more deprived areas, and age and performance status were associated with higher incidence of comorbidities. Advanced stage was associated with a lower risk of severe comorbidity burden.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335374,1790013037,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE OPEN   \nClinical Studies  \nComorbidity in patients with cancer treated at The Christie  \nAzadeh Abravan 1,2 ✉, Corinne Faivre-Finn1,2, Fabio Gomes2, Marcel van Herk1,2 and Gareth Price1,2  \n© The Author(s) 2024, corrected publication 2024  \nBACKGROUND: Comorbidities have been shown to impact the presentation and treatment of patients with cancers. This study investigates the prevalence and patterns of comorbidity in a pan-cancer cohort of patients treated at a large UK specialist cancer center over a 9-year period.  \nMETHODS: A retrospective review of 77,149 patients from 01/01/2014 to 15/12/2022 was conducted using the Adult Comorbidity Evaluation 27 score (ACE-27) to assess the burden of comorbidities across 12 organ systems and an overall comorbidity burden. Binary and multinomial logistic regressions were utilized to evaluate the relationships between comorbidity incidence and demographic and socio-economic factors.  \nRESULTS: At the time of diagnosis, 59.7% of patients had at least one comorbidity, with the highest prevalence in lung cancer and the lowest in brain/CNS and endocrine gland cancers. Cardiovascular comorbidities were the most frequent. Comorbidity severity was higher in patients from more deprived areas. Age and performance status were associated with a higher incidence of all comorbidities examined. Patients with advanced stage had a lower risk of having a severe comorbidity burden.  \nCONCLUSION: Comorbidities are common across all cancers but are more prevalent in certain patient populations. Further research to understand the implications of comorbidities in cancer management is needed.  \nBritish Journal of Cancer (2024) 131:1279–1289; [https://doi.org/10.1038/s41416-024-02838-w](https://doi.org/10.1038/s41416-024-02838-w)  \nBACKGROUND  \nPatients with cancer often present with a level of comorbidity at diagnosis, which can have a signiﬁcant impact on their overall health, cancer care, and treatment outcomes [1]. Comorbidity, which encompasses psychological and physiological conditions, broadly refers to the presence of one or more health conditions that frequently coexist with a primary medical ailment [2]. It can impact the patient’s prognosis for a primary disease such as cancer. Comorbidity can have both positive and negative effects on the timing of cancer diagnosis [3]. Earlier diagnosis may happen when a comorbid patient is followed up routinely for their condition, while delayed diagnosis may occur when a patient or healthcare professional disregards cancer symptoms as they think it might come from pre-existing conditions [3–5]. Comorbidities can contribute to the progression of cancer through various mechanisms, such as inducing local and systemic inﬂammation and altering the tumor immune environment [3]. Comorbidities can affect the life expectancy and survival of the patients with cancer, independent of cancer stage and disease status [6, 7].  \nThe prevalence of comorbidity in patients with cancer depends on both the cancer type and the studied population. For example, older cancer survivors are at high risk for multimorbidity [8], and as such patients diagnosed with lung or colorectal cancer tend to have a higher level of comorbidities, as these cancers often occur in older individuals. Some comorbidities are accompanied by an increased risk of developing certain types of cancer. For example, obesity and diabetes have been linked to an increased risk of  \ndeveloping colorectal, postmenopausal breast, and pancreatic cancer [9] . According to research conducted by Fowler et al. [10] and Balic et al. [11], diabetes, a prevalent comorbidity, has been associated with increasing the incidence rates of both liver and pancreatic cancer. On the other hand, as reported by Tsilidis et al.  \n[12], diabetes was associated with reduced risk of prostate cancer.  \nComorbidities can also pose challenges in the management of cancer. It c","cbCaidWxizdjR1QY","https://ap.wps.com/l/cbCaidWxizdjR1QY","pdf",435662,11,"English","# Background\n## Definition and clinical impact of comorbidity\n## Prevalence depends on cancer type and studied population\n## Management challenges and trial participation\n# Methods and analysis\n## Retrospective cohort and time window\n## ACE-27 comorbidity assessment\n## Logistic regression and studied covariates\n# Results\n## Prevalence at diagnosis and organ system patterns\n## Factors linked to higher severity and incidence\n# Conclusion\n## Key findings and need for further research","[{\"question\":\"What was the aim of this study on comorbidity in cancer patients?\",\"answer\":\"To investigate the prevalence and patterns of comorbidity in a pan-cancer cohort treated at The Christie over a 9-year period.\"},{\"question\":\"How were comorbidities measured and analyzed?\",\"answer\":\"A retrospective review of 77,149 patients used the Adult Comorbidity Evaluation 27 (ACE-27) to assess comorbidity burden across 12 organ systems and overall burden, with binary and multinomial logistic regressions to test relationships with demographic and socio-economic factors.\"},{\"question\":\"What patient factors were associated with higher comorbidity incidence or severity?\",\"answer\":\"Comorbidity severity was higher in patients from more deprived areas, and age and performance status were associated with higher incidence of comorbidities. Advanced stage was associated with a lower risk of severe comorbidity burden.\"}]","Comorbidity in patients with cancer treated at The Christie - Clinical Studies - Prevalence and patterns using ACE-27 | PDF",1790010734,28]